Fleming Harold Edward 4
4 · CRISPR Therapeutics AG · Filed Jun 14, 2021
Insider Transaction Report
Form 4
Fleming Harold Edward
Director
Transactions
- Award
Stock Option (Right to Buy)
2021-06-10+25,000→ 25,000 totalExercise: $123.71Exp: 2031-06-10→ Common Shares (25,000 underlying)
Footnotes (1)
- [F1]This option was granted on June 10, 2021 with respect to 25,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments.